Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Auris Medical Holding Ltd. announced that the Nasdaq Hearings Panel has granted the Company’s request for the continued listing of the Company’s securities on The Nasdaq Capital Market.
ADOCIA announces its financial results, including revenue and cash position, for the quarter ended March 31st, 2019.
Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.
Somerset, NJ-based CRO Catalent announced it is acquiring Baltimore-based Paragon BioServices for $1.2 billion.
NOXXON Pharma N.V. announced its financial results for the fiscal year ending December 31, 2018.
Polyphor AG shareholders approved all motions put forward by the Board of Directors to the 22nd Annual General Meeting in Basel.
The shareholders in Recipharm AB (publ), reg. no. 556498-8425, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Monday 13 May 2019 at 3.00 pm at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden.
The new accounting standard, IFRS 16 will have an estimated positive impact on EBITDA of SEK 90 million in 2019.
Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.